TY - JOUR
T1 - Establishment and characterization of a new mammary adenocarcinoma cell line derived from MMTV neu transgenic mice
AU - Sacco, Maria Grazia
AU - Gribaldo, Laura
AU - Barbieri, Ottavia
AU - Turchi, Gino
AU - Zucchi, Ileana
AU - Collotta, Angelo
AU - Bagnasco, Luca
AU - Barone, Domenico
AU - Montagna, Cristina
AU - Villa, Anna
AU - Marafante, Erminio
AU - Vezzoni, Paolo
N1 - Funding Information:
The technical assistance of Dario Strina, Lucia Su-sani, Valeria Fasolo, and Enrica Mira Catò is acknowledged. We thank Dr. Silvana Canevari for her useful suggestions and Ms. Sophie Bevan for her typing of the manuscript. The financial support of AIRC to AV is gratefully acknowledged. The work was also partly supported by a grant from PF ACRO of CNR. This is manuscript no. 8 of the Genome 2000/ITBA Project funded by CARIPLO.
PY - 1998
Y1 - 1998
N2 - A new murine cell line, named MG1361, was established from mammary adenocarcinomas arising in a MMTV-neu transgenic mouse lineage where breast tumors develop in 100% of females, due to the overexpression of the activated rat neu oncogene in the mammary gland. The MG1361 cell line shows an epithelial-like morphology, has a poor plating efficiency, low clonogenic capacity, and a doubling time of 23.8 hours. Karyotype and flow cytometry analysis revealed a hypotetraploid number of chromosomes, whereas cell cycle analysis showed 31.2% of cells to be in the G1 phase, 21.4% in S and 47.4% in G2 + M. This cell line maintains a high level of neu expression in vitro. The MG1361 cell line was tumorigenic when inoculated in immunodeficient (nude) mice and the derived tumors showed the same histological features as the primary tumors from which they were isolated. MG1361 cells were positive for specific ER and PgR binding which was competed by tamoxifen, making this cell line useful for the evaluation of endocrine therapy. Moreover, they were sensitive to etoposide treatment, suggesting that they could be a model for the study of chemotherapy-induced apoptosis. As the tumors arising in MMTV-neu transgenic mice have many features in common with human mammary adenocarcinomas, this cell line can be utilized to perform basic studies on the role of the neu oncogene in the maintenance of the transformed phenotype, and to test novel protocols of therapeutic strategies.
AB - A new murine cell line, named MG1361, was established from mammary adenocarcinomas arising in a MMTV-neu transgenic mouse lineage where breast tumors develop in 100% of females, due to the overexpression of the activated rat neu oncogene in the mammary gland. The MG1361 cell line shows an epithelial-like morphology, has a poor plating efficiency, low clonogenic capacity, and a doubling time of 23.8 hours. Karyotype and flow cytometry analysis revealed a hypotetraploid number of chromosomes, whereas cell cycle analysis showed 31.2% of cells to be in the G1 phase, 21.4% in S and 47.4% in G2 + M. This cell line maintains a high level of neu expression in vitro. The MG1361 cell line was tumorigenic when inoculated in immunodeficient (nude) mice and the derived tumors showed the same histological features as the primary tumors from which they were isolated. MG1361 cells were positive for specific ER and PgR binding which was competed by tamoxifen, making this cell line useful for the evaluation of endocrine therapy. Moreover, they were sensitive to etoposide treatment, suggesting that they could be a model for the study of chemotherapy-induced apoptosis. As the tumors arising in MMTV-neu transgenic mice have many features in common with human mammary adenocarcinomas, this cell line can be utilized to perform basic studies on the role of the neu oncogene in the maintenance of the transformed phenotype, and to test novel protocols of therapeutic strategies.
KW - Apoptosis
KW - Breast cancer
KW - Hormone responsiveness
KW - MG 1361
KW - MMTV-neu transgenic mice
KW - Mammary adenocarcinoma cell line
UR - http://www.scopus.com/inward/record.url?scp=14444275536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=14444275536&partnerID=8YFLogxK
U2 - 10.1023/A:1005988715285
DO - 10.1023/A:1005988715285
M3 - Article
C2 - 9497105
AN - SCOPUS:14444275536
SN - 0167-6806
VL - 47
SP - 171
EP - 180
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -